Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pelthos Therapeutics Inc.CHRO · Entity 6798 | Chief Medical Officer | June 14, 2024 | June 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pelthos Therapeutics Inc.
Report date June 14, 2024 · Filed June 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2034-06-14 | Direct | 154,223 |
Reported balance
After 2024-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-14 · Grant · Acquired 130,000 · Balance 154,223 F1: On June 14, 2024, the Reporting Person was granted stock options to purchase 130,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 14, 2024, the Reporting Person was granted stock options to purchase 130,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2024 Filed Jun 19, 2024 00:05 UTC | Pelthos Therapeutics Inc. CHRO · Entity 6798 | GrantStock Option · Derivative | 130,000 | Not disclosed Strike: $1.30 | Not disclosed |
DisclosureSEC source: 0001753926-24-001135 · ownership.xml · derivative · entry 1 Lang Eric · CIK 0001984967 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,223 Underlying: Common Stock · 130,000 shares Expires 2034-06-14 F1 · price: On June 14, 2024, the Reporting Person was granted stock options to purchase 130,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years. F1 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted stock options to purchase 130,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.